
GSK's Kim Branson on driving innovation with AI and machine learning
Eureka!
00:00
New modalities and generating training data
Kim highlights oligonucleotide design as a data-driven modality requiring bespoke encoder models and investments in data-generation platforms.
Play episode from 18:30
Transcript


